A Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated LDL-C
Latest Information Update: 03 Feb 2026
At a glance
- Drugs Antihyperlipidaemics (Primary)
- Indications Hyperlipidaemia; Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeBetter Med
Most Recent Events
- 03 Feb 2026 New trial record